- 2016 Medical Marijuana Conference, all presentationsOriginal Date: July 09-10, 2016This discounted package includes all of the individual presentations from the conference.12.0 CEUs (5.0 general and 7.0 pharmacy) approved by OBNM
- The History of Cannabis and an Overview of the Endocannabinoid SystemPresenter: Janice Vaughn Knox, MDOriginal Date: July 9, 2016The endocannabinoid system (ECS) is still relatively unknown to medical professionals as well as the lay public. There are thousand of articles that are written yet, the information is little known. Little is it realized that every physiological system is touched and modulated by the ECS. In fact, one’s very life, health and wellness is predicated on their ECS tone. In order to understand the implications of the ECS, one must understand the historical events that led to the discovery of the very powerful ECS.This presentation is intended to “wet” everyone’s appetite to learn more about this incredible and real physiological system and how to apply one’s medical knowledge to manipulate the ECS for treatment and cure of many diseases that plague our population.1.5 general CEUs approved by OBNM
- Cannabis Component: Cannabinoids, Terpenoids, Flavonoids and Even AlkaloidsPresenter: Ethan Russo, MDOriginal Date: July 9, 2016Beyond the psychoactive tetrahydrocannabinol (THC), in recent years, the pharmacologically versatile and non-intoxicating phytocannabinoid, cannabidiol (CBD), has come into focus for its benefits on epilepsy, anxiety, psychosis and as an anti-inflammatory analgesic with no significant drug-abuse liability. Several other phytocannabinoids with interesting pharmacology are illustrated. Similarly, the cannabis terpenoids are potent modulatory and synergistic components of cannabis that contribute to analgesia, mood modulation and attenuate side effects of THC. These are highlighted in context along with the promising cannabis flavonoids and root alkaloids.1.0 pharmacy CEUs approved by OBNM
- Central Sensitization, Glial Activation and the Potential Benefits of Cannabis and other BotanicalsPresenter: Kevin Wilson ND,DAAPMOriginal Date: July 9, 2016With the developing understanding that chronic pain is not well managed, and even aggravated by opioid medications, this presentation attempts to explain why many conventional medications aggravate pain, via the mechanism of glial cell activation and central sensitization. With the goal of better pain management, and possibly the avoidance of other neurodegenerative conditions, cannabis and other botanical medicines are explored for their well-documented CNS protection and benefit.1.5 general CEUs approved by OBNMVaporization of Cannabis: Why it is a Superior MedicinePresenter: Michelle Sexton, NDOriginal Date: July 9, 2016Most cannabis users still report that they smoke cannabis using a variety of methods. Vaporization is an efficient and healthier means for rapid delivery and allows for the terpenoid fraction delivery "intact" and in the same proportions as in the whole plant. This talk discusses vapor pressures and boiling points and meaning of these as well as additives to or "cutting" of concentrates with such compounds as propylene glycol and vegetable glycerine. The loss and reapportionment of the terpene fraction and its' contributions to the whole plant medicine in specific cases are discussed. How to navigate terpene profiles and what they mean in the "indica"/ "sativa" name game is also covered.1.0 general CEUs approved by OBNMInternational Standards for Cannabis Testing and Quality ControlPresenter: Jahan Marcu, Ph.DOriginal Date: July 10, 2016Patient Focused Certification (PFC) is a 3rd party certification program focused on Cannabis product safety. PFC was developed by Americans for Safe Access (ASA) a medical Cannabis advocacy organization. ASA set the standards in the U.S. for medical Cannabis product safety and best practices for manufacturing, dispensing, cultivation, and laboratory operations. The PFC program is working around the world to implement existing standards and best practices for patients, providers of medical care, companies, regulatory bodies and legislators.PFC compliance requires defined processes, documented procedures, validated methods adverse event tracking, recall plans, among other criteria, which help to ensure that Cannabis products have a specific composition and are free of harmful contaminants. PFC’s international program is headquartered at the International Cannabis and Cannabinoids Institute (ICCI) in cooperation with ASA. The ICCI founders share a combined experience that includes clinical and basic research, direct patient advocacy, legislative efforts and studies, government relations, advisory and administration, medical informatics, the creation of product safety protocols such as quality control/quality assurance standards and laboratory analysis for the cultivation, manufacturing and distribution of Cannabis products and global entrepreneurship.1.5 general CEUs approved by OBNMClinical Endocannabinoid DeficiencyPresenter: Ethan Russo, MDOriginal Date: July 10, 2016Several years ago, a concept of clinical endocannabinoid deficiency (CED) was developed, hypothesizing that it might explain the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and some other disorders in which cannabinoid medicines seem to provide unique relief. Certain biochemical evidence and pathophysiological relationships lend credence to the concept.For example, in migraine, the endocannabinoid, anandamide potentiates 5-HT1A and inhibits 5-HT2A receptors Ananadamide is also tonically active in the periaqueductal gray matter, a migraine generator and key central pain locus. Additionally, fibromyalgia is now conceived as a central sensitization state with secondary hyperalgesia. Idiopathic bowel syndrome has similar features. Thethree conditions are frequently co-morbid, and a susceptible patient may progress from one syndrome to others over the course of their lives. Based on this evidence, it was suggested that an underlying clinical endocannabinoid deficiency might be treated successfully and appropriately with cannabinoid medicines. This talk briefly reviews these data, but also highlights recent research that supports the concept:1) Further investigation has demonstrated that anandamide is integral to pathophysiological mechanisms of vascular control, sterile inflammation and central neuropathic pain generation inbrainstem structures in the trigeminovascular system (Akerman et al.)2) In female migraineurs, observed increased anandamide degradation in platelets, and reduced serum anandamide levels may explain decreased pain thresholds (Cupini et al.)3) Cerebrospinal fluid samples from migraineurs demonstrate suppression of anandamide levels (Sarchielli et al.)4) THC statistically significantly reduced electrically-induced and spontaneous daily pain scores in fibromyalgia patients (Schley et al.)5) Sativex reduces peripheral neuropathic pain and allodynia scores (Numikko et al.)6) Anandamide co-localizes with cholinergic in human colon and inhibit contraction of circular and longitudinal muscle via a non-CB1 mechanism (Smid et al.)Further approaches to investigating clinical endocannabinoid deficiency including biochemical experiments and clinical trial designs are also presented.1.0 pharmacy CEUs approved by OBNMCannabis as an AdaptogenPresenter: Michelle Sexton, NDOriginal Date: July 10, 2016The concept that Cannabis could be considered a tonic that can restore balance is not a new one, nor one based on “euphoric” bias of the user. The construct of the endocannabinoid system supports that supplementation of this system with phytocannabinoids may be a strategy for imbalance across systems.Cannabinoids have been shown to modulate a host of potential biomarkers for allostasis: antioxidant capacity, cytokines, nitric oxide, and cortisol regulation. It is by these effectors that the eCS broadly modulates inflammation, neuronal function and metabolism.Given that our world is synonymous with stress, inflammation associated with stress is a major culprit in reprogramming a host of biochemistry. This talk focuses on clinical management of various presentations of stress-related clinical presentations.1.0 pharmacy CEUs approved by OBNMCannabinoids and the GutPresenter: Eric Yarnell, ND, RH(AHG)Original Date: July 10, 2016A review of the physiology of cannabinoid receptors and cannabinoids specific to the gut, including cross-talk with the gut flora and system results of this system including effect on adipose, is presented at length. The role of the endogenous cannabinoid system in regulating intestinal permeability are highlighted. Clinical implications of these basic science aspects are also presented.1.5 pharmacy CEUs approved by OBNMA Brief Discussion of the Potential Adverse Effects of Cannabis UsePresenter: Matt Noble, MD MPHOriginal Date: July 10, 2016This presentation includes a brief review of some of the basic clinical effects of cannabis, before a review and discussion of the preliminary data of an ongoing prospective study of human exposures as reported to the Oregon Poison Center. It focuses on potential and observed adverse effects. We also review cannabinoid hyperemesis syndrome, including clinical presentation/effects and putative pharmacokinetic explanations and treatment strategies. Finally, we briefly discuss medications that may be contraindicated in cannabis users.2.0 pharmacy CEUs approved by OBNM
